Document is current

Article History

Received: 29 February 2024

Accepted: 28 September 2024

First Online: 9 October 2024

Declarations

:

: The study received Pearl Institutional Review Board ethical exemption (22-ADRW-135) and was conducted adhering to European Pharmaceutical Market Research Association guidelines and Adelphi Real World standard operating procedures. The physicians provided written consent to participate in the DSP.

: Not applicable.

: NC declares being a consultant for Boehringer Ingelheim during the development of this study, payment for consultancy activities from Boehringer Ingelheim and Roche, speaker fees from Boehringer Ingelheim, Roche and AstraZeneca, and participation in advisory boards from Boehringer Ingelheim and Roche. PS declares being a consultant for Boehringer Ingelheim during the development of this study, payment for consultancy activities and an institutional grant from PPM Services, speaker fees, participation on an advisory board and an institutional grant from Boehringer Ingelheim, institutional grants from Roche, consultancy activities for Jucabio, GlycoCore Pharma, Veracyte and Pieris, consulting and speaker fees from Chiesi, and participation on advisory boards for AstraZeneca and Structure Therapeutics. CV declares being a consultant for Boehringer Ingelheim during the development of this study. VCA is an employee of Boehringer Ingelheim International GmbH. O-TC, LL and MS are employees of Adelphi Real World. MK declares being a consultant for Boehringer Ingelheim during the development of this study.